BLPH Bellerophon Therapeutics Inc.

0.67
+0.01  (+2%)
Previous Close 0.66
Open 0.67
Price To Book 4.48
Market Cap 46,332,909
Shares 68,906,765
Volume 418
Short Ratio
Av. Daily Volume 222,878

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b cohort 2 data and pivotal cohort 3 (Phase 3) initiation due 2H 2019.
INOpulse delivery device
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
Phase 3 trial stopped due to futility - August 7, 2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2b trial planned.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)
Phase 2 data due later in 2019.
INOpulse delivery device
Pulmonary hypertension associated with Sarcoidosis (PH-Sarcoidosis)

Latest News

  1. Bellerophon to Present at the JMP Securities Life Sciences Conference
  2. Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease
  3. Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
  4. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
  5. Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
  6. Bellerophon Therapeutics: 1Q Earnings Snapshot
  7. Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results
  8. What Kind Of Shareholders Own Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)?
  9. Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
  10. Did Changing Sentiment Drive Bellerophon Therapeutics’s (NASDAQ:BLPH) Share Price Down A Painful 76%?
  11. Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
  12. Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients  
  13. Bellerophon Announces Closing of $7 Million Public Offering of Common Stock
  14. Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock
  15. Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
  16. Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
  17. Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results
  18. DBV Technologies Appoints Daniel Tassé as Chief Executive Officer